620 related articles for article (PubMed ID: 27410923)
1. Ipilimumab for Patients with Relapse after Allogeneic Transplantation.
Davids MS; Kim HT; Bachireddy P; Costello C; Liguori R; Savell A; Lukez AP; Avigan D; Chen YB; McSweeney P; LeBoeuf NR; Rooney MS; Bowden M; Zhou CW; Granter SR; Hornick JL; Rodig SJ; Hirakawa M; Severgnini M; Hodi FS; Wu CJ; Ho VT; Cutler C; Koreth J; Alyea EP; Antin JH; Armand P; Streicher H; Ball ED; Ritz J; Bashey A; Soiffer RJ;
N Engl J Med; 2016 Jul; 375(2):143-53. PubMed ID: 27410923
[TBL] [Abstract][Full Text] [Related]
2. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies.
Khouri IF; Fernandez Curbelo I; Turturro F; Jabbour EJ; Milton DR; Bassett RL; Vence LM; Allison JP; Gulbis AM; Sharma P
Clin Cancer Res; 2018 Mar; 24(5):1011-1018. PubMed ID: 29246938
[No Abstract] [Full Text] [Related]
3. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells.
Zhou J; Bashey A; Zhong R; Corringham S; Messer K; Pu M; Ma W; Chut T; Soiffer R; Mitrovich RC; Lowy I; Ball ED
Biol Blood Marrow Transplant; 2011 May; 17(5):682-92. PubMed ID: 20713164
[TBL] [Abstract][Full Text] [Related]
4. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
6. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.
Bashey A; Medina B; Corringham S; Pasek M; Carrier E; Vrooman L; Lowy I; Solomon SR; Morris LE; Holland HK; Mason JR; Alyea EP; Soiffer RJ; Ball ED
Blood; 2009 Feb; 113(7):1581-8. PubMed ID: 18974373
[TBL] [Abstract][Full Text] [Related]
7. TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation.
Moatti A; Debesset A; Pilon C; Beldi-Ferchiou A; Leclerc M; Redjoul R; Charlotte F; To NH; Bak A; Belkacemi Y; Salomon BL; Issa F; Michonneau D; Maury S; Cohen JL; Thiolat A
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387779
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.
Nikiforow S; Kim HT; Daley H; Reynolds C; Jones KT; Armand P; Ho VT; Alyea EP; Cutler CS; Ritz J; Antin JH; Soiffer RJ; Koreth J
Haematologica; 2016 Oct; 101(10):1251-1259. PubMed ID: 27354021
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
[TBL] [Abstract][Full Text] [Related]
10. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
11. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.
Ijaz A; Khan AY; Malik SU; Faridi W; Fraz MA; Usman M; Tariq MJ; Durer S; Durer C; Russ A; Parr NNC; Baig Z; Sagar F; Ali Z; McBride A; Anwer F
Biol Blood Marrow Transplant; 2019 Jan; 25(1):94-99. PubMed ID: 30195074
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
13. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
Penter L; Zhang Y; Savell A; Huang T; Cieri N; Thrash EM; Kim-Schulze S; Jhaveri A; Fu J; Ranasinghe S; Li S; Zhang W; Hathaway ES; Nazzaro M; Kim HT; Chen H; Thurin M; Rodig SJ; Severgnini M; Cibulskis C; Gabriel S; Livak KJ; Cutler C; Antin JH; Nikiforow S; Koreth J; Ho VT; Armand P; Ritz J; Streicher H; Neuberg D; Hodi FS; Gnjatic S; Soiffer RJ; Liu XS; Davids MS; Bachireddy P; Wu CJ
Blood; 2021 Jun; 137(23):3212-3217. PubMed ID: 33720354
[TBL] [Abstract][Full Text] [Related]
14. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.
Davids MS; Kim HT; Costello C; Herrera AF; Locke FL; Maegawa RO; Savell A; Mazzeo M; Anderson A; Boardman AP; Weber A; Avigan D; Chen YB; Nikiforow S; Ho VT; Cutler C; Alyea EP; Bachireddy P; Wu CJ; Ritz J; Streicher H; Ball ED; Bashey A; Soiffer RJ; Armand P
Blood; 2020 Jun; 135(24):2182-2191. PubMed ID: 32478814
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.
Yeh AC; Brunner AM; Spitzer TR; Chen YB; Coughlin E; McAfee S; Ballen K; Attar E; Caron M; Preffer FI; Yeap BY; Dey BR
Biol Blood Marrow Transplant; 2014 May; 20(5):730-4. PubMed ID: 24530972
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
17. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
[TBL] [Abstract][Full Text] [Related]
18. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
Georges GE; Maris M; Sandmaier BM; Malone DG; Feinstein L; Niederweiser D; Shizuru JA; McSweeney PA; Chauncey TR; Agura E; Little MT; Sahebi F; Hegenbart U; Pulsipher MA; Bruno B; Forman S; Woolfrey AE; Radich JP; Blume KG; Storb R
Int J Hematol; 2002 Aug; 76 Suppl 1():184-9. PubMed ID: 12430851
[TBL] [Abstract][Full Text] [Related]
19. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
Slavin S; Nagler A; Naparstek E; Kapelushnik Y; Aker M; Cividalli G; Varadi G; Kirschbaum M; Ackerstein A; Samuel S; Amar A; Brautbar C; Ben-Tal O; Eldor A; Or R
Blood; 1998 Feb; 91(3):756-63. PubMed ID: 9446633
[TBL] [Abstract][Full Text] [Related]
20. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
